Sandoz Group AG (SDZ.SW)
The price, the headline numbers and the latest news, in one place.
Sandoz Group AG (SDZ.SW) Stock Price, Analysis & Data
| Bid | n/a |
| Market Cap | 31.95B |
| Revenue (ttm) | 11.68B |
| Net Income (ttm) | 646M |
| 0.49 | |
| 1.17 | |
| 63.11 | |
| 20.22 | |
| P/B (ttm) | 4.47 |
| P/S (ttm) | 2.74 |
| Earnings Date | Feb 17, 2027 |
| Ask | n/a |
| Volume | 660,105 |
| Avg. Volume (20D) | 753,717 |
| Open | 73.34 |
| Previous Close | 73.60 |
| Day's Range | 73.18 - 74.22 |
| 52-Week Range | 43.86 - 75.90 |
| Analyst | Buy |
| Price Target | 72.48 (-1.84%) |
| Dividends | $0.8 (1.08%) |
| Ex-Dividend Date | Apr 13, 2026 |
About SDZ.SW
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage...
Financial Performance
In 2025, Sandoz's revenue was 11.16B, an increase of 7.44% compared to the previous year's 10.38B. Earnings were 914M, an increase of undefined%.
Financial numbers in CHF Financial StatementsAnalyst Forecast
According to 16 analyst ratings, the average rating for SDZ.SW stock is "Buy". The 12-month stock price forecast is 72.48, which is downside of 1.84% from the latest price.
Stock ForecastsAnalysts project revenue of ... Upgrade
2 weeks ago · The Wall Street Journal
Sandoz in Talks With U.S. Government About Potential Investment, CEO SaysSandoz Group is in talks with the U.S. government about manufacturing investments in the country and doesn’t see President Trump’s planned tariffs on generic medicines as a major threat, the drugmaker...